Smart Scaling: How Fractional and Contract Talent Solves Biotech’s Biggest Growth Challenges
Summary: Life sciences companies facing shorter runways and constrained funding are turning to fractional and contract talent to access specialized expertise without permanent overhead. The model works best for leadership and specialist functional roles such as CMO, CTO, CSO, VP/SVP, and Interim Directors across discipline-specific functions, where project-aligned engagement delivers strategic value during critical development phases. Finding the right fractional fit requires deep networks and therapeutic-area expertise that most companies don't have in-house. The math has changed for life sciences companies.
According to EY's 2025 Biotech Beyond Borders report, 39% of biotechs now have less than 12 months of cash runway, the highest level in at least six years. And for early-stage companies, the picture is even more challenging: private biotech financings in the first half of 2025 fell more than 20% compared to the same period last year, with median deal sizes contracting across Series A and B rounds.
When your runway is uncertain, and every hire could impact your next funding round, the traditional approach of building out a full permanent leadership team may create more risk than it solves. It's why forward-thinking life sciences companies are turning to fractional and contract talent as a strategic advantage.
Why Are Life Science Companies Turning to Fractional Leadership?
Shorter cash runways and cyclical project needs are making permanent senior leadership commitments a strategic liability rather than an advantage. The shift toward fractional talent in life science reflects a fundamental change in how biotech companies operate. It's happening on both sides of the equation.
On the company side, shorter runways mean organizations can't, or strategically shouldn't, commit to permanent senior leadership salaries when project needs are cyclical. A Series A biotech needs deep regulatory expertise now, but may not need a full-time Head of Regulatory, VP Clinical Operations, or biostatistics leader for another 18 months.
On the talent side, experienced professionals are increasingly choosing fractional work. Harvard Business Review found that LinkedIn profiles mentioning fractional roles grew from 2,000 in 2022 to over 110,000 by early 2024. In biopharma specifically, a recent BioSpace poll showed 22% of professionals have fractional experience, with another 54% actively considering it.
“We continue to see comparatively lower levels of investment flowing into biotech than into sectors such as fintech or broader big tech,” says Richard Johnson at Discover International. “From an investor perspective, biotech is often perceived as a higher-risk environment, characterised by long development cycles, regulatory uncertainty, and complex capital requirements. As a result, many companies are becoming increasingly disciplined in how they deploy capital, prioritising flexibility and operational resilience over large fixed-cost commitments. That is driving greater interest in fractional leadership and specialist expertise.”
This isn't a compromise. It's becoming the sophisticated approach to accessing senior expertise while preserving capital. And for investors who specialize in biotech and MedTech, these leaner companies are often more attractive: undervalued, strategically focused, and well-positioned for acquisition. Fractional leadership helps companies stay nimble enough to reach those outcomes.
Which Roles Are Best Suited for Fractional Leadership?
Not every role fits the fractional model, but several categories have emerged as particularly well-suited for flexible arrangements in life sciences.
Chief Medical Officer
Senior medical leadership during the transition from preclinical to clinical development, particularly when companies are preparing for first-in-human studies, designing Phase 1/2 trial protocols, or building the medical narrative that will hold up to investor and regulatory scrutiny. Fractional CMOs are often engaged when a company has a strong scientific foundation but no in-house clinician to author the medical sections of IND/CTA filings, chair safety review committees, manage KOL relationships, and represent the clinical story to FDA, EMA, and prospective partners. These engagements ramp up around regulatory interactions and trial start-up milestones, then settle into a steady advisory cadence once studies are enrolling.
Chief Technology Officer and Chief Scientific Officer
R&D leadership during critical development phases, particularly when companies need to advance platform technology, scale manufacturing processes, or make complex scientific and technical decisions. Fractional operational and technical leaders are often brought in by investors when founding teams (frequently with academic backgrounds) need commercialization, technical operations, or scientific strategy expertise. These engagements tend to be highly hands-on, spanning everything from investor meetings to R&D prioritization and operational problem-solving.
Clinical, Regulatory, and Biostatistics Leadership
These are SOME of the most sought-after areas for fractional talent in early-stage biotech. Companies developing assets in competitive spaces like GLP-1 therapeutics, radiopharmaceuticals, or precision oncology often require specialist expertise in clinical development, regulatory strategy, or biostatistics during intensive phases of trial design, data analysis, and regulatory submission preparation.
VP/SVP and Interim Functional Leadership
Companies increasingly engage fractional VP/SVPs or Interim Directors across functions such as Regulatory Affairs, Clinical Operations, Technical Operations, Manufacturing, Quality, Commercial, and Market Access. These leaders provide experienced oversight during periods of rapid growth, restructuring, fundraising, or milestone delivery without requiring long-term fixed overhead.
The challenge? These aren't professionals you'll find through a job posting. The most effective fractional leaders are the ones with directly relevant therapeutic expertise and a track record of guiding companies through your specific stage, and they operate almost entirely through their networks and referrals. They're rarely on the open market at all.
The Strategic Advantages—And Why Fit Matters More Than Ever
The financial case for fractional talent is straightforward. Portal Innovations estimates 25-40% savings compared to traditional senior leadership hires. But the strategic advantages run deeper, and realizing them depends entirely on finding the right match.
Instantaneous Expertise
Fractional consultants bring accumulated knowledge from multiple biotech engagements. A fractional CSO advising on your cell therapy manufacturing scale-up or a biostatistics consultant supporting pivotal trial analysis has likely navigated similar challenges at multiple companies recently. They've seen what works and what doesn't. They’re bringing learned experience that your permanent team may lack. But that value only materializes if their therapeutic background actually aligns with your science. A leader with deep oncology experience won't deliver the same impact for a CNS-focused program.
Project-Aligned Scheduling
Biotech projects have natural peaks and troughs. A fractional regulatory or biostatistics leader might work intensively during clinical trial design or regulatory submissions, then step back while waiting for EMA or FDA responses. You're paying for expertise when you need it and not carrying overhead during the waiting periods inherent to drug development. Making this work requires understanding which professionals genuinely operate this way versus those seeking a bridge to their next permanent role.
On-Demand Strategic Access
Think of it like outside legal counsel: available when critical decisions arise, without carrying the overhead during quieter periods. When your CDMO flags a manufacturing issue, your clinical data requires specialist interpretation, or an investor meeting demands technical expertise, your fractional leader is a call away. The key is identifying professionals who approach these engagements as true partnerships, not transactional arrangements.
How Do You Structure a Successful Fractional Engagement?
The fractional model delivers results when structured thoughtfully, and when you start with the right person.
Contract length matters. One common mistake: offering contracts that are too short. Three-month engagements create instability. The best fractional talent seeks longer commitments, typically six to twelve months, with honest discussions about early termination if circumstances change. A fractional CTO or CSO leading your R&D through a critical development phase needs enough runway to make a meaningful impact.
Address concerns proactively. Common objections around IP protection, cultural embedding, and relationship quality are manageable with the right approach. Stronger NDAs establish clear boundaries from day one. Setting integration expectations early ensures fractional doesn't mean disconnected.
Match expertise to stage. The right fractional leader isn't just someone with an impressive title. It's someone whose therapeutic expertise and company-stage experience align with your specific needs. A biostatistics leader experienced in adaptive trial design brings a different value than one focused primarily on post-market data analysis. This matching requires deep knowledge of who's actually available, what they've accomplished, and how they approach fractional engagements.
Finding the Right Fractional Fit
Smart scaling means matching talent solutions to your company's actual stage and needs. For life sciences organizations navigating constrained funding environments, fractional and contract arrangements provide specialized expertise without permanent overhead—preserving runway for what matters most.
But the model only works when you find fractional leaders who genuinely fit: professionals with relevant therapeutic expertise, experience at your company's stage, and an approach to these engagements that prioritizes partnership over transaction.
That's where most companies hit a wall. The fractional talent pool is growing rapidly, but it's largely invisible, operating through referrals, specialized networks, and relationships built over years within specific therapeutic areas. You're not searching for any available CTO, CSO, VP Regulatory Affairs, or Interim Clinical Operations Director. You're searching for the one who's guided similar companies through your exact challenge, understands your regulatory pathway, and is genuinely available for the engagement model you need.
This is the work we do at Discover International. Our networks span the specialized corners of life sciences where fractional leaders operate, from regulatory affairs professionals navigating FDA submissions to biostatistics consultants supporting pivotal trials and technical operations leaders scaling manufacturing. We know who's available, what they've accomplished, and whether their approach will fit your organization. When you need fractional expertise that delivers real strategic value, we connect you with professionals who hit the ground running because they've been here before.
